MAPT and Alzheimer disease: Biomarkers like decreased Aβ levels in cerebrospinal fluid (CSF) and the identification of Aβ deposits or tau accumulation in the brain through positron emission tomography (PET) imaging aid in assessing and monitoring the advancement of AD pathology [23,24,25].